NCT07557706RecruitingPhase 1
Using taVNS to Modulate Cardiovascular Function in Individuals With Neurologic Disease
Source: ClinicalTrials.gov · Last updated 18 Jun 2026
Brief summary (registry, in English)
The purpose of this study is to find out whether a type of gentle nerve stimulation, called transcutaneous auricular Vagus Nerve Stimulation (taVNS), can help improve how the body regulates heart rate and blood pressure in people with Parkinson's Disease (PD). Problems with heart rate and blood pressure control are common and can make it harder for people to exercise or do daily activities. By using this non-invasive form of nerve stimulation and testing how it affects the body's natural responses, this study hopes to learn if taVNS could be a helpful tool to support physical therapy and improve overall function.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- First submitted
- 17 Mar 2026
- Start date
- 15 Sept 2025
- Primary completion date
- 31 Aug 2026
- Lead sponsor
- University of Alabama at Birmingham
- Diseases
- Parkinson disease
- NCT number
- NCT07557706
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 24
- From 15 Sept 2025 to the primary completion date, 31 Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Sustained severe hypertension (\>/= 180/110 mmHg while seated)
- Significant uncontrolled cardiac arrhythmia
- Unstable angina
- Congestive heart failure
- History of myocardial infarction
- History of seizures
- Severe cognitive impairment
Other
- Use of beta blockers
- Pregnant women or women who are planning to become pregnant
Who the study is looking for
- Diagnosis of idiopathic PD
- Stable medication for at least 4 weeks prior to the study
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Wellness, Health and Research Facility at UAB Coordinator of this site? Confirm its status | Birmingham | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.